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Abstract: Induced Pluripotent Stem Cells (iPSCs) can be differentiated into epithelial organoids that
recapitulate the relevant context for CFTR and enable testing of therapies targeting Cystic Fibrosis
(CF)-causing mutant proteins. However, to date, CF-iPSC-derived organoids have only been used to
study pharmacological modulation of mutant CFTR channel activity and not the activity of other
disease-relevant membrane protein constituents. In the current work, we describe a high-throughput,
fluorescence-based assay of CFTR channel activity in iPSC-derived intestinal organoids and describe
how this method can be adapted to study other apical membrane proteins. Specifically, we show how
this assay can be employed to study CFTR and ENaC channels and an electrogenic acid transporter
in the same iPSC-derived intestinal tissue. This phenotypic platform promises to expand CF therapy
discovery to include strategies that target multiple determinants of epithelial fluid transport.
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1. Introduction
There has been remarkable progress made in the use of patient tissue-derived primary organoids for the in vitro modeling of Cystic Fibrosis (CF) pathogenesis and testing
of therapies targeting mutant Cystic Fibrosis Transmembrane Conductance Regulator
(CFTR) [1–5]. CFTR mutations lead to the loss of CFTR expression and/or function as a
cyclic AMP-regulated anion channel at the cell surface. In three-dimensional (3D) primary
organoids, the addition of forskolin results in higher intracellular cAMP, which activates
CFTR channel activity and leads to swelling of the luminal cavity [2]. CFTR mutations
that are associated with CF reduce forskolin-dependent swelling while also enabling the
ranking of therapeutic interventions targeting defective CFTR expression and function [2,6].
Organoid swelling has been shown to correlate with multiple clinical biomarkers of CF,
such as high sweat chloride concentration and compromised lung function measured
as FEV1 [6]. This demonstrates the relevance of patient-derived organoids for in vitro
assessment of patient-specific responses to modulators that directly target mutant CFTR.
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However, such 3D structures have not been useful for screening the activities of
cation channels and electrogenic transporters implicated in net epithelial fluid absorption.
Previously, 2D monolayer cultures were generated from enzymatically dissociated rectal
organoids to provide direct access to the apical membrane [7]. However, while these 2D
cultures enabled low-throughput electrophysiological assays of CFTR-mediated chloride
conductance, they did not reconstitute the native functional expression of ENaC, even
though this channel is known to be expressed in the large intestine [8].
Merkert et al. developed 2D intestinal epithelial cultures from CF-Induced Pluripotent
Stem Cells (iPSC) and demonstrated the potential of this model for high-throughput drug
screening of novel CF therapies [5]. In this case, a halide sensitive reporter protein (eYFP)
was genetically integrated, enabling studies of anion channel activity. As of yet, no similar
strategy has been developed for the study of cation channels in iPSCs [9].
We reasoned that enzymatic dissociation of the 3D organoids as in the above study
is too disruptive [7] and that by allowing the organoids to open to form a 2D lawn, we
would preserve apical expression of physiologically relevant, sodium-dependent channels
and transporters. In the current work, we show that the “opening” procedure does, in
fact, retain 3D expression levels of ENaC and is adaptable to medium–high-throughput,
high-content, phenotypic analyses.
Given the importance of ENaC and sodium-dependent transporters for modifying
net epithelial fluid transport and maintaining epithelial barrier function, there is a clear
need for the development of robust models and assays to test these activities and their
modulation. It has been proposed that they could serve as potential molecular targets for
companion therapies to augment the impact of approved CFTR modulators drugs [9–11].
Further, with the adaptation of these methods to the study of patient-specific tissues, we
augment the diagnostic toolkit required for precision medicine.
2. Materials and Methods
2.1. ESC (Embryonic Stem Cell) and iPSC-Derived Human Intestinal Organoids (HIO)
Table 1 defines the ESC and iPSC lines employed for organoid differentiation. H1derive ESC HIOs were provided by Cincinnati Children’s Hospital Pluripotent Stem Cell
Facility (PSCF). iPSCs were provided by the Cystic Fibrosis Individualized Therapy (CFIT)
Program [12]. CRISPR-edited isogenic controls for the iPSC lines (non-CF1 and non-CF2)
were generated by the Centre for the Commercialization of Regenerative Medicine as
previously described [12]. Briefly, CRISPR-Cas9 with CFTR-targeted gRNA and Wt ssODN
repair was used to generate correction of the homozygous mutation (F508del).
Table 1. Definition of ESC and iPSC lines used for organoid differentiation.
ESC and iPSC Lines

CFTR Genotype

Description and Source

CF 1
Non-CF 1
Non-CF 2
H1

F508del/F508del
Wt/Wt
Wt/Wt
Wt/Wt

iPSC / CFIT Program 1
iPSC / CFIT Program 1
iPSC / CFIT Program 1
ESC / Cincinnati Children’s Hospital 2

1

CF Canada-Sick Kids Program for Individualized CF Therapy (CFIT). 2 Cincinnati Children’s Hospital Pluripotent Stem Cell Facility (PSCF).

Human intestinal organoids were differentiated as previously described [13]. In
brief, iPSCs were cultured on Matrigel® (Corning Inc., NewYork, NY, USA, CACB356231)
coated plates in mTeSR1 media (STEMCELL Technologies, Vancouver, BC, Canada, 5850).
At approximately 60% confluency, differentiation to definitive endoderm was initiated
through the addition of Activin-A (100 ug/uL, R&D Systems, Minneapolis, MI, USA, 338AC-050) for 3 days. Cultures were then exposed to hindgut endoderm differentiation media
containing FGF4 (500 ng/mL, R&D Systems, 235-F4-025) and Chiron99021 (3 µM, R&D
Systems, 4423/10) for 4 days. Post-hindgut differentiation, budding immature organoids
were collected and embedded into 50 µL solid Matrigel® (Corning Inc., CACB356231) drops.
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Spheroids were cultured for 30 days in previously established growth factor conditioned
media [14].
After maturation, HIOs were passaged every 7–10 days and media was changed
once every 2 days. To passage organoids, organoids were first collected in ice-cold PBS
(Wisent, St. Bruno, QC, Canada, 311-010-CL) and pelleted through centrifugation for
5 min at 300× g at 4 ◦ C. Post-centrifugation, excess PBS (Wisent, 311-010-CL), Matrigel®
(Corning Inc., CACB356231) and cellular debris was aspirated. The pelleted organoids were
re-suspended in 1 mL of GCDR (STEMCELL Technologies, 7174) and incubated at room
temperature for 5 min. With a P1000 pipettor, the organoids were fragmented through
pipetting 40–60 times. Organoid fragments were then pelleted through centrifugation
and re-suspended in fresh Matrigel® (Corning Inc., CACB356231) domes and seeded at a
1:3 ratio. Growth factor conditioned medium was added to after allowing the Matrigel®
(Corning Inc., CACB356231) to solidify at 37 ◦ C for 35 min. Detailed descriptions of HIOs
are listed in Table 1.
2.2. MDCK and MDCK (Tagged αβγENaC) Cells
As previously described [15], both MDCK and MDCK (HA-tagged αENaC, myctagged βENaC, FLAG-tagged γENaC) cells are grown in DMEM media (Invitrogen,
Waltham, MA, USA, 12634010), supplemented with 10% FBS (Wisent, 320-005-CL), 1%
Penicillin/Streptomycin solution (Wisent, 450-200-EL) and additional selection antibiotics
(300µg/mL G418 (Wisent, 400-130-IG), 100µg/mL Hygromycin B (Thermofisher, Waltham,
MA, USA, 10687010) and 2µg/mL Puromycin (Thermofisher, A1113802)). MDCK cells
are cultured in the presence of Amiloride (10 µM, Spectrum Chemical, New Brunswick,
NJ, USA, TCI-A2599-5G). Twenty-four hours prior to ASC assay, αENaC expression in
MDCK cells was induced with dexamethasone (1 µM, Sigma-Aldrich, St. Louis, MI, USA,
D4902) and sodium butyrate (10µM, Sigma-Aldrich, B5887) to enhance protein expression
of ENaC subunits.
2.3. Swelling Assay
iPSC-derived organoids were isolated from the Matrigel® support using ice-cold HBSS
(Hank’s Balanced Salt Solution, Wisent, 311-513-CL) and pelleted through centrifugation
at 500 g for 5 min. The cell pellet was re-suspended in HBSS containing 3 µM of live cell
maker dye, Calcein-AM (Sigma-Aldrich, St. Louis, MO, USA, 17783) at 37 ◦ C for 45 min.
Excess dye was removed through centrifugation, and organoids were re-suspended in
DMEM/F12 (Invitrogen, 12634010) for human intestinal organoids. Organoid swelling
was induced using Fsk (Sigma-Aldrich, F3917) for non-CF organoids or Fsk in combination
with CFTR potentiators. Human intestinal organoid swelling was performed in 96-well
plates, with each condition containing at least 50 organoids per biological replicate. The
swelling was tracked for 4 h and imaged at 15 min intervals using confocal microscopy
(Nikon A1R Confocal Laser Microscope).
Organoid swelling analysis was performed using Cell Profiler v3.1 (Cambridge, MA,
USA). Swelling images were analyzed using an in-house developed algorithm, as previously described [10]. In brief, images were exported as individual TIFF files and aligned
using translation registration by cross-correlation. A histogram-derived thresholding
method (triangle) was used to identify specific organoids in the images. The center of the
object mask was used to track individual organoids throughout the experiment. The differential organoid size at each time point was calculated by subtracting the size of the initial
timepoint. Organoids were excluded if they were not tracked for the entire time course.
2.4. Opened Organoid Cultures
Organoids were removed from the Matrigel® (Corning Inc., Corning, NY, USA,
CACB356231) domes and collected in ice-cold DMEM/F12 (Invitrogen, 12634010) and
pelleted through centrifugation at 500× g for 5 min. Pellets were then re-suspended
in growth factor conditioned medium and plated onto Poly-L-Lysine (0.01% solution,
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Sigma-Aldrich, P4707) coated plates (Corning Inc., 3916). Organoids were collected and
suspended at a density of approximately 1000 organoids per 1 mL of media. This suspension was used to seed wells in a 96-well plate such that after opening, 50% of the surface
area is covered (Figure S1). Media were changed one-day post-seeding. All functional
studies were conducted two days after organoid plating. With the apical application of
specific electrochemical gradients, ligands and inhibitors, we selectively measure the apical
electrogenic membrane protein function.
2.5. Apical Chloride Conductance (ACC) Assay for CFTR Function
The ACC assay was used to assess CFTR-mediated changes in membrane depolarization using methods previously described [16]. In summary, opened iPSC-derived intestinal
organoids were incubated with zero sodium, chloride and bicarbonate buffer (150 mM
NMDG (Sigma-Aldrich, M2004), 150 mM Gluconic Acid Lactone (Sigma-Aldrich, G4750),
3 mM Potassium Gluconate (Sigma-Aldrich, P1847), 10 mM Hepes (Bioshop, Burlington, ON, Canada HEP001.5), pH 7.42, 300 mOsm) containing 0.5 mg/mL of FLIPR® dye
(Molecular Devices, San Jose, CA, USA R8042) for 30 min at 37 ◦ C. The Wt-CFTR function in iPSC-derived gene-edited organoids was measured after the acute addition of Fsk
(10 µM, Sigma-Aldrich, F3917) or DMSO (0.1%, Sigma-Aldrich, M81802) control. In iPSCderived F508del CF organoids, cells were chronically rescued with corrector compounds
for 24 h using 3 µM VX-809 (Selleck Chemicals, Houston, TX, USA, S1565), 3 µM VX-445
(MedChemExpress, Monmouth Junction, NJ, USA, HY-111772) / 3 µM VX-661 (Selleck
Chemicals, S7059) or DMSO control. Post-CF corrector modulator rescue, the F508delCFTR function was measured after the acute addition of 10 µM Fsk (Sigma-Aldrich, F3917)
and 1 µM VX-770 (Selleck Chemicals, S1144). Additional modulators (8cGMP (SigmaAldrich, 15992), GSNO (Cayman Chemicals, Ann Arbor, MI, USA, 82240), Milrinone
(Sigma-Aldrich, M4659) and Tadalafil (Sigma-Aldrich, SML1877)) were added during the
FLIPR® dye-loading process. CFTR functional recordings were measured using the FLIPR®
Tetra High-throughput Cellular Screening System (Molecular Devices), which allowed for
simultaneous image acquisition of the entire 96-well plate. Images were first collected to
establish baseline readings over 5 min at 30 s intervals. Modulators were then added to
stimulate CFTR-mediated anion efflux. Post-drug addition, CFTR-mediated fluorescence
changes were monitored, and images were collected at 15 s intervals for 70 frames. CFTR
channel activity was terminated with the addition of 10 µM CFTRInh172 (CF Foundation
Therapeutics), and fluorescence changes were monitored at 30 s intervals for 25 frames.
2.6. Apical Sodium Conductance (ASC) Assay for ENaC Function
The ASC assay was used to assess ENaC inhibition upon amiloride addition through
assessing changes in membrane hyperpolarization. Opened iPS-derived intestinal organoids
were incubated with a physiological sodium gluconate buffer (150 mM Sodium Gluconate
(Sigma-Aldrich, G9005), 3 mM Potassium Gluconate (Sigma-Aldrich, P1847), 10 mM Hepes
(Bioshop, HEP001.5), pH 7.42, 300 mOsm), containing FLIPR® dye (0.5 mg/mL), for
30 min at 37 ◦ C [17]. After dye loading, the plate was transferred to the FLIPR® Tetra
High-throughput Cellular Screening System (Molecular Devices). Baseline readings were
acquired for 5 min at 30 s intervals. In opened organoids, ENaC inhibition was measured
following the acute addition of Amiloride (10 µM or 50 µM, Spectrum Chemical, TCI-A25995G), Phenamil (10 µM or 50 µM, Sigma-Aldrich, P203) or DMSO control. Inhibitor-mediated
membrane hyperpolarization was tracked over time as a loss in fluorescence signal over
70 min at 60 s intervals.
2.7. Apical Amino Acid Conductance (AAC) Assay for SLC6A14 Function
The AAC assay was used to measure SLC6A14-mediated acute uptake of Arginine
leading to membrane depolarization. iPSC-derived gene-edited organoids and F508del CF
organoids (rescued chronically for 24 h with VX-809 or DMSO control) were incubated in a
low-sodium, low-chloride buffer (112.5 mM NMDG (Sigma-Aldrich, M2004), 112.5 mM
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Gluconic Acid Lactone (Sigma-Aldrich, G4750), 36.25 mM NaCl (Sigma-Aldrich, S9888),
2.25 mM Potassium Gluconate (Sigma-Aldrich, P1847), 0.75 mM KCl (Sigma-Aldrich,
P3911), 0.75 mM CaCl2 (Sigma-Aldrich, C1016), 0.5 mM MgCl2 (Sigma-Aldrich, M8266)
and 10 mM HEPES (Bioshop, HEP001.5), pH 7.42, 300 mOsm), containing FLIPR® dye
(0.5 mg/mL) for 40 min at 37 ◦ C [18]. During dye loading, organoids were treated with
α-MT (2 mM, Sigma-Aldrich, M8377) or buffer control. After dye loading, the plate was
transferred to the FLIPR® Tetra High-throughput Cellular Screening System (Molecular
Devices). Baseline readings were acquired for 5 min at 30 s intervals. Arginine (1 mM)
was added acutely to opened organoids pretreated with SLC6A14 blocker, α-MT [19,20].
Change in fluorescence was recorded at 30 s intervals.
2.8. FLIPR Analysis and Heatmap Generation
Experiments were exported as multi-frame TIFF images, for which every frame is
recorded in the entire plate. Pixels outside of the well areas were filtered out using the
initial signal intensities, and wells containing opened organoids were separated. All traces
were normalized to the last point of the baseline intensity. Peak response for each pixel was
calculated as the maximum deviation from baseline. During the stimulation segment, the
fluorescence intensity increased for CFTR and decreased for ENaC function. A heatmap
representation was generated from the peak response of each pixel, and the mean response
trace of wells was generated by averaging the corresponding pixel traces. The CFTR
and ENaC-dependent FLIPR signals described are independent of cell number, as we are
reporting the average of peak responses detected across an entire scan. The resolution
of the image enables measurement from 2–3 cells per pixel. The analysis methods were
previously described in detail [16].
2.9. Real-Time Quantitative PCR
As previously described [21], 4 wells of 96-well plate at 40–50% confluency of opened
organoid samples were collected per sample in ice-cold Phosphate Buffered Saline and
pelleted through centrifugation at 500 g for 5 min. Total mRNA from pelleted samples
was extracted using RNeasy® Plus Micro Kit (Qiagen, 74004), following the enclosed
instructions. After confirming the spectrophotometric quality of extracted RNA through
260/280 ratios of 2.0 and 260/230 ratios of 1.8–2.2, mRNA samples with concentrations
greater than 300 ng/µL were used to reverse transcribe 1 µg of cDNA using the iScriptTM
cDNA Synthesis Kit (BioRad, 170-8891). Expression levels of target genes were measured
using primers listed in Table 2 using the FX96 TouchTM Real-Time PCR Detection System
using the SYBR Green Master Mix containing the EvaGreen® Fluorophore with low ROX
(BioRad, 58343). The expression of the target genes was normalized to housekeeping gene
control TBP (TATA Box binding Protein) [10]. Primer sequences for gene expression studies
are listed in Table 2.
Table 2. List of primers used for RT-qPCR studies.
Primer Sequence
CFTR
αENaC
SLC6A14
EpCAM
Villin
MUC2
TBP

Fwd: 50 -CGGAGTGATAACACAGAAAGT-30
Rev: 50 -CAGGAAACTGCTCTATTACAGAC-30
Fwd: 50 -TTGACGTCTCCAACTCACCG-30
Rev: 50 -GGCAGAGGAGGACAAAGGTC-30
Fwd: 50 -GCTTGCTGGTTTGTCATCACTCC-30
Rev: 50 -TACACCAGCCAAGAGCAACTCC-30
Fwd: 50 -AACACAAGACGACGTGGACA-30
Rev: 50 -GCTCTCCGTTCACTCTCAGG-30
Fwd: 50 -CTGTGATGTCCAGCGACTGT-30
Rev: 50 -CTCTCTGGCCCATTCCACTG-30
Fwd: 50 -GCTGCTATGTCGAGGACACC-30
Rev: 50 -GGGAGGAGTTGGTACACACG-30
Fwd: 50 -CAAACCCAGAATTGTTCTCCTT-30
Rev: 50 -ATGTGGTCTTCCTGAATCCCT-30
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2.10. Immunofluorescence
Four wells of opened organoids were collected from 96-well plates. Organoids were
fixed and permeated with 100% methanol at −20◦ C for 10 min. Post-methanol incubation,
samples were washed 3 times with PBS, 5 min per wash, at room temperature. Following
the washes, samples were blocked using 4% BSA for 30 min and incubated with primary
antibodies against CDX2 (1:100, Abcam, ab76541) or Zona Occluden-1 (ZO-1) (1:200, Thermofisher, 61-7300) and CFTR overnight. After the removal of the primary antibody, samples
were washed 3 times with PBS, 5 min per wash, and incubated with secondary antibodies
(Alexa Fluor 594 Monoclonal (Thermofisher, R37119) and Alexa Fluor 488 Polyclonal Antibody (Thermofisher, R37114)) and nuclear marker DAPI (1:400, Thermofisher, D1306) for
1 h. Samples were then washed 3 times with PBS, 5 min per wash, at room temperature.
Confocal images were taken using Nikon A1R Confocal Laser Microscope.
2.11. Western Blotting
Samples were collected in ice-cold PBS and pelleted through centrifugation at 4 ◦ C
(500× g for 7 min). Post-centrifugation, the cell pellet was re-suspended in 200 µL of
modified radioimmunoprecipitation assay buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM
EDTA, pH 7.4, 0.2% (v/v) SDS and 0.1% (v/v) Triton X-100) containing a protease inhibitor
cocktail for 10 min. After centrifugation at 13,000 rpm for 5 min, the soluble fractions
were analyzed by SDS-PAGE on 6% Tris-Glycine gel. After electrophoresis, proteins were
transferred to nitrocellulose membranes and incubated in 5% milk, and CFTR bands were
detected using the mouse monoclonal antibody 596 (1:1000, UNC CFTR antibodies). CFTR
expression is measured relative to the internal loading control protein, calnexin. Calnexin
(CNX, Sigma-Aldrich, C4731) was detected using a Calnexin-specific rabbit polyclonal
antibody (1:5000). MDCK and MDCK (tagged αβγENaC) cell lysates were αENaC, βENaC,
and γENaC subunits were detected using antibodies against the epitope tags, anti-HA
(BioLegend, San Diego, CA, USA, 901503), anti-Myc (Millipore, Burlington, MA, USA, 05724), and anti-Flag antibodies (Cell Signaling, Danvers, MA, USA, 14793S). In MDCK and
MDCK (tagged αβγENaC) cell, αENaC, βENaC, and γENaC expressions are measured
relative to internal loading control protein, Actin (Sigma-Aldrich, A228). After primary
antibody incubation, blots were washed 3 times with PBS and incubated in secondary
antibodies Anti-rabbit IgG (Abcam, ab6721) and Anti-mouse IgG (Abcam, ab6789) (1:5000).
The blots were developed using the Li-Cor Odyssey Fc (LI-COR Biosciences, Lincoln, NE,
USA) in a linear range of exposure (1–20 min).
2.12. Statical Analysis
One-way ANOVA with Tukey’s multiple comparison was performed on data with
more than two datasets. Unpaired t-test was performed on data with two datasets. Statistical analysis was performed using Graphpad Prism version 9.2.0 (San Diego, CA, USA).
p < 0.05 was considered to be significant.
3. Results
3.1. 3D CF Human Intestinal Organoids (HIO) Exhibit Defective Fluid Secretion, Which Can Be
Restored through the Use of CFTR Modulators or Gene Editing
HIOs were differentiated from Embryonic Stem Cells (H1 ESC line) and iPSC lines
(non-CF1 and non-CF2 (n = 2) and CF1 (n = 1), see Table 1) using previously established
differentiation protocols (Figure 1a) [13,14]. Immunostaining confirmed that the CF1 and
non-CF1 HIOs expressed CDX2, and Zona Occludin-1 (ZO-1), which are characteristic
of intestinal epithelial cells (Figure 1b). A similar spheroid morphology was detected
regardless of the CFTR genotype, in contrast to previous studies comparing primary CF
and non-CF rectal organoids (2). We expected a smaller luminal cavity size in CF HIOs. The
appearance of a lumen under baseline, unstimulated conditions in CF organoids suggests
the contribution of non-CFTR channels that remain to be identified.
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CFTR, exhibited an increase in size after activation by the adenylate cyclase agonist, Forskolin (Fsk), unlike the organoids differentiated from CF iPSCs (CF1). These findings are
expected and confirm that CF intestinal organoids lack CFTR-mediated forskolin-induced
swelling (Figure 1c,d) [2].
In CF HIOs, a defective F508del-CFTR function (impaired Fsk-induced swelling) was
rescued by treatment with the CFTR corrector, lumacaftor (VX-809) for 24 h, followed
7 of 17by
acute potentiation with ivacaftor (VX-770) (Figure 1c,d), as expected from previous studies [14].
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technical replicate = average of >30 organoids). Box plot depicts the median value and bounds depict
IQR ranges with the whiskers defining the minima and maxima values.

However, a primary functional difference was revealed by comparing Fsk-induced
swelling. HIOs differentiated from mutation corrected non-CF1 iPSCs, which harbors
Wt-CFTR, exhibited an increase in size after activation by the adenylate cyclase agonist,
Forskolin (Fsk), unlike the organoids differentiated from CF iPSCs (CF1). These findings are
expected and confirm that CF intestinal organoids lack CFTR-mediated forskolin-induced
swelling (Figure 1c,d) [2].
In CF HIOs, a defective F508del-CFTR function (impaired Fsk-induced swelling) was
rescued by treatment with the CFTR corrector, lumacaftor (VX-809) for 24 h, followed
by acute potentiation with ivacaftor (VX-770) (Figure 1c,d), as expected from previous
studies [14].
3.2. Opened HIOs Enable Direct Assessment of Apical Wt-CFTR Channel Function in a
High-Throughput Format
Electrophysiological assays of CFTR modulator activity in 2D intestinal monolayer
cultures are considered the “gold standard” for testing efficacy. However, these methods
are relatively low throughput. Thus, we were prompted to develop a complementary 2D
model and assay of CFTR function that would enable direct measurement of F508del-CFTR
channel modulation at the apical membrane of the HIOs.
As previously demonstrated using primary mouse colonic organoids [10], the removal
of the supporting extracellular matrix led to the splitting open of organoids and direct
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CFTR channel modulation at the apical membrane of the HIOs.
As previously demonstrated using primary mouse colonic organoids [10], the removal of the supporting extracellular matrix led to the splitting open of organoids and
direct access to the apical membrane. We applied this method to the study of iPSC-derived
HIOs to generate 2D opened organoids (Figure 2a). Characterization studies (RT-qPCR)
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confirmed there was no significant reduction in the expression of ENaC, and the electrogenic amino acid transporter, SLC6A14, and other intestinal and epithelial cell markers,
when comparing 2D opened organoids to 3D HIOs (Figure 2b, Figure S2). In addition, we
show that mature CFTR protein (band C) is expressed in 3D HIOs and opened HIOs, albeit
access to the apical membrane. We applied this method to the study of iPSC-derived HIOs
the abundance is reduced in the opened structure in this study (Figure 2c).
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organoids, compared to expression in a Human Bronchial Epithelial (HBE) cell line. HBE cells expressing either WT-CFTR
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measured in opened HIOs using the Apical Chloride Conductance (ACC) assay (Figure

Immunofluorescence studies were conducted to confirm apical membrane location
through visualization of tight junction complex protein, Zona Occluden-1 (ZO-1) and
CFTR expression in the opened non-CF HIOs (Figure 2d). Interestingly, there appeared
to be discrete cell types that express relatively high apical expression of CFTR. Singlecell analytical methods will be employed to identify the cells with high CFTR signals in
the future.
After the confirmation of CFTR protein expression, CFTR channel function was measured in opened HIOs using the Apical Chloride Conductance (ACC) assay (Figure 3a),
as previously shown in mouse colonic organoids [10]. From 3D H1 HIOs (Table 1), we
subsequently generated opened organoids to test CFTR-mediated changes in membrane
potential following Fsk stimulation. After generating H1 opened organoids, cultures treated
with Fsk displayed an increase in fluorescence. CFTR stimulation was measured as an
average fluorescence increase across the entire well. CFTR function was inhibited with
addition of CFTRInh-172 (Figure 3b,c). We then measured CFTR responses in the non-CF
opened HIOs, expressing Wt-CFTR (Table 1, Figure 3d). The opened non-CF HIOs showed
excellent reproducibility of peak response stimulation and consistent activation kinetics
with Fsk stimulation and inhibition with CFTRInh-172, reporting a Z’ factor of 0.5294,
supporting its utility as a robust assay of dynamic CFTR function in a high-throughput
format (Figure 3e, Video S1). To demonstrate reproducibility across different iPSC lines, we
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subsequently generated opened organoids to test CFTR-mediated changes in membrane
potential following Fsk stimulation. After generating H1 opened organoids, cultures
treated with Fsk displayed an increase in fluorescence. CFTR stimulation was measured
as an average fluorescence increase across the entire well. CFTR function was inhibited
with addition of CFTRInh-172 (Figure 3b,c). We then measured CFTR responses in the
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non-CF opened HIOs, expressing Wt-CFTR (Table 1, Figure 3d). The opened non-CF HIOs
showed excellent reproducibility of peak response stimulation and consistent activation
kinetics with Fsk stimulation and inhibition with CFTRInh-172, reporting a Z’ factor of
0.5294, supporting its utility as a robust assay of dynamic CFTR function in a highdifferentiated and generated opened organoids from another non-CF line (non-CF2) to assess
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effective modulator combination, VX-661 (3 µM), VX-445 (3 µM) and VX-770 (1 µ
(TRIKAFTATM) [24], restored F508del-CFTR function to approximately 50% of Wt-CF
function of non-CF HIOs (Figure 4b–d).
To determine if iPSC HIOs have the potential to identify companion therapies for C
we assessed the effects of known modulators of PKA and PKG phosphorylation since
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phosphorylation of CFTR by PKA and PKG kinases have been implicated in regulat
modulator efficacy (Figure 4e) [25,26]. After partial correction of the F508del traffick
defect using VX-809, opened F508del CF1 HIOs were acutely potentiated with Fsk/VX-7
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We were prompted to determine if the ACC assay is effective in both detecting the
rescued F508del-CFTR activity [16,18]. Alternatively, opened F508del CF1 HIOs w
primary defect caused by the F508del mutation and evaluating the efficacy of clinical
treated with phosphodiesterase inhibitors (Milrinone or Tadalafil), which have be
modulators on opened CF HIOs (Figure 4a). The opened F508del CF1 HIOs displayed no
shown to be effective in the stimulation of F508del-CFTR short circuit currents in mur
significant fluorescence changes with Fsk stimulation without modulator rescue, which is
intestinal tissue [26]. Milrinone addition, along with VX-809/VX-770, significantly
consistent with the expected defect in F508del-CFTR channel function prior to modulator
creased the Fsk response to levels comparable to the triple modulator combination (V
rescue (Figure 4b). VX-809 (3 µM)/VX-770 (1 µM) treatment resulted in significant partial
661/VX-445/VX-770) treatment (Figure 4e,f). Therefore, the ACC assay is sufficiently s
rescue of the mutant F508del-CFTR protein [23]. Further treatment with the new and
sitive and precise to distinguish between various modulator combinations that are
highly effective modulator combination, VX-661 (3 µM), VX-445 (3 µM) and VX-770 (1 µM)
pected to exhibit different efficacies in rescuing the functional expression of F508del-CFT
(TRIKAFTATM
) [24], restored F508del-CFTR function to approximately 50% of Wt-CFTR
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Figure 4. Opened CF HIOs can model defective CFTR function and response to CF modulators.
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phosphorylation of CFTR by PKA and PKG kinases have been implicated in regulating
modulator efficacy (Figure 4e) [25,26]. After partial correction of the F508del trafficking
defect using VX-809, opened F508del CF1 HIOs were acutely potentiated with Fsk/VX-770
in combination with a nitric oxide (NO) agonist, which targets the enhancement of the PKG
phosphorylation pathway (8cGMP or GSNO) and has been reported to augment VX-809
rescued F508del-CFTR activity [16,18]. Alternatively, opened F508del CF1 HIOs were treated
with phosphodiesterase inhibitors (Milrinone or Tadalafil), which have been shown to
be effective in the stimulation of F508del-CFTR short circuit currents in murine intestinal
tissue [26]. Milrinone addition, along with VX-809/VX-770, significantly increased the Fsk
response to levels comparable to the triple modulator combination (VX-661/VX-445/VX770) treatment (Figure 4e,f). Therefore, the ACC assay is sufficiently sensitive and precise to
distinguish between various modulator combinations that are expected to exhibit different
efficacies in rescuing the functional expression of F508del-CFTR. Direct access to the apical
membrane of HIOs in the opened format prompted us to determine whether the functional
output of other apical membrane channels can be detected.
3.4. Measurement of ENaC Specific Activity in MDCK Overexpression Cells
With access to the apical membrane, we now have the opportunity to study other
apical membrane channels and transporters that have been implicated in CF pathophysiology [9,11,27–29]. Since ENaC is functionally expressed in the intestinal epithelium [30] but
has not been studied in a high-throughput manner in patient-derived primary intestinal
organoids [7], we were prompted to develop a novel assay ENaC measuring mediated
changes of membrane potential in opened organoids.
As a proof-of-concept, we first determined if the FLIPR® membrane potential dye is
capable of measuring ENaC function in a well-characterized cell line either lacking ENaC
expression or overexpressing ENaC. This involved the use of the renal epithelial MDCK
cell line, genetically engineered to express an HA-tagged αENaC, a myc (and T7)-tagged
βENaC and a FLAG-tagged γENaC and its non-transfected parental MDCK control line
(Figure 5a) [27]. In order to measure the constitutive ENaC function, we modified the
existing ACC assay measuring the CFTR function and established an inward driving
sodium gradient to assess the effect of ENaC inhibitors, amiloride and phenamil, on the
apical membrane of confluent, differentiated MDCK monolayers. Under these conditions,
we predicted that the apical membrane potential, as monitored by the novel Apical Sodium
Conductance (ASC) assay, would hyperpolarize upon inhibition of ENaC with amiloride
or phenamil (Figure 5b).
As expected, MDCK cells expressing tagged αβγENaC also exhibited membrane
hyperpolarization after the addition of either amiloride or phenamil at both 10 and 50 µM
concentrations only in the presence of extracellular sodium (Figure 5c,d). In the absence of
extracellular sodium, the addition of amiloride 10 or 50 µM does not result in membrane
hyperpolarization (Figure S3), which demonstrates that the membrane hyperpolarization
effect with the addition of amiloride is sodium-dependent. These responses were significantly greater in the MDCK cells expressing tagged αβγENaC relative to the parental
line. At 10 µM concentrations of these inhibitors, with phenamil known to be highly
specific for ENaC, there was a clear and significant difference between the transfected and
un-transfected MDCK lines. These findings support the claim that this ASC assay captures
ENaC activity. At the higher concentration of these inhibitors of 50 µM, there was still
a significant difference between transfected and untransfected cells. However, there is a
possibility that 50 uM of these inhibitors could inhibit NHE3 [31], and through changes in
intracellular pH, indirectly affect other channels.
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Similar to the ACC assay of the CFTR channel function (Figure 2d), the ASC assay of
ENaC function in opened iPSC-derived HIOs showed excellent reproducibility and a consistent amiloride response, resulting in a Z’ factor of 0.573. Such parameters indicate the
opened model and ASC assay together provide an excellent candidate platform for monitoring dynamic and high-throughput drug screening of potential ENaC modulators (Fig13 of 17
ure S4, Video S2), further validating the suitability of the ASC opened HIOs
for drug
screening and the evaluation of modulator efficacy (Figure S4).

Figure 6. Opened iPSC-differentiated HIOs enable a high-throughput assessment of ENaC-specific
inhibition.
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3.6. Specific Activity of Sodium and Chloride-dependent Amino Acid Transporter, SLC6A14,
Similar
to Be
theMeasured
ACC assay
of theCF
CFTR
channelHIOs
function (Figure 2d), the ASC assay
Can
in Opened
and Non-CF
of ENaC function in opened iPSC-derived HIOs showed excellent reproducibility and a
Previously, the opened organoid model was applied to mouse colonic organoids in
consistent amiloride response, resulting in a Z’ factor of 0.573. Such parameters indicate
order to determine the activity of the sodium-dependent amino acid transporter, SLC6A14
the opened model and ASC assay together provide an excellent candidate platform for
[10]. SLC6A14 is a sodium- and chloride-dependent electrogenic amino acid transporter
monitoring dynamic and high-throughput drug screening of potential ENaC modulators
expressed in airway, intestinal and colonic epithelial tissues. SLC6A14 mediates the up(Figure S4, Video S2), further validating the suitability of the ASC opened HIOs for drug
take of cationic and neutral amino acids, along with two sodium ions and one chloride
screening and the evaluation of modulator efficacy (Figure S4).
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pressed in ies
airway,
intestinal and colonic epithelial tissues. SLC6A14 mediates the uptake
should block SLC6A14-mediated amino acid uptake [10,20]. As expected, this signal was
of cationic and neutral amino acids, along with two sodium ions and one chloride ion, genabolished when pretreated with α-MT (Figure 7a–c) [10,19]. Stimulation with acute L-Arg
erating one net positive charge translocation and membrane depolarization per amino acid
treatment and blockage of this stimulation using α-MT suggests that functional measuretransport [10,19]. Through the application of a low-sodium/chloride extracellular gradient,
ments of SLC6A14 amino acid uptake can be achieved using opened HIOs. Hence, there is
SLC6A14-mediated depolarization could also be measured in opened HIOs (Figure 7a). In
the potential to identify SLC6A14 modulators in this platform for use in both CF and nonthe presence of low extracellular sodium and chloride, the addition of arginine (L-Arg)
CF intestinal tissue.
to the apical surface of these opened organoids evokes apical membrane depolarization
in both opened non-CF and CF HIOs. Based on previous mechanistic studies [20], the
pretreatment using the SLC6A14 blocker, α-Methyl-DL-tryptophan (α-MT) should block
SLC6A14-mediated amino acid uptake [10,20]. As expected, this signal was abolished
when pretreated with α-MT (Figure 7a–c) [10,19]. Stimulation with acute L-Arg treatment
and blockage of this stimulation using α-MT suggests that functional measurements of
SLC6A14 amino acid uptake can be achieved using opened HIOs. Hence, there is the potential to identify SLC6A14 modulators in this platform for use in both CF and non-CF
intestinal tissue.
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Figure 7. Opened iPSC-derived HIOs enable specific measurement of SLC6A14 activity. (a) Representative trace of SLC6A14
activity in opened non-CF HIOs pre-treated with either vehicle control or inhibitor, α-MT (2 mM). Opened HIOs were acutely
with Arg
(1 mM). (b) Box
and enable
whisker specific
plot of SLC6A14
function with
acute treatment
of Arg
mM) in non-CF trace of
Figuretreated
7. Opened
iPSC-derived
HIOs
measurement
of SLC6A14
activity.
(a)(1Representative
HIOs. SLC6A14 activity was inhibited with pre-treatment of specific inhibition α-MT (2 mM) (*** p = 0.0001, **** p < 0.0001,
SLC6A14
activity in opened non-CF HIOs pre-treated with either vehicle control or inhibitor, α-MT (2 mM). Opened HIOs
n = 4 biological replicates, n = 3 technical replicates). (c) Box and whisker plot shows SLC6A14 activity with acute treatment
were acutely
treated with Arg (1 mM). (b) Box and whisker plot of SLC6A14 function with acute treatment of Arg (1 mM)
with Arg (1 mM) or in presence of specific inhibitor α-MT (2 mM) in iPSC CF HIOs (** p = 0.0080, # p = 0.0023, n = 3 biological
in non-CF HIOs. SLC6A14 activity was inhibited with pre-treatment of specific inhibition α-MT (2 mM) (*** p = 0.0001, ****
replicates, n = 3 technical replicates). Box plot depicts the median value and bounds depict IQR ranges with the whiskers
p < 0.0001, n = 4 biological replicates, n = 3 technical replicates). (c) Box and whisker plot shows SLC6A14 activity with
defining the minima and maxima values.

acute treatment with Arg (1 mM) or in presence of specific inhibitor α-MT (2 mM) in iPSC CF HIOs (** p = 0.0080, # p =
0.0023, n = 3 biological replicates, n = 3 technical replicates). Box plot depicts the median value and bounds depict IQR
4. Discussion
ranges with the whiskers defining the minima and maxima values.
In the current work, we described novel methods for studying sodium-dependent,
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show that SLC6A14 is functionally expressed in the apical membrane of CF and non-CF
intestinal organoids differentiated from iPSC. Interestingly, we did not observe a similar
augmentation of F508del-CFTR activity in human intestinal organoids by agonists of
nitric oxide (Figure 4f). For the reason discussed above, future studies are required to
fully understand the role of SLC6A14 in the modification of human intestinal disease in
CF patients.
In summary, we demonstrated the ability to detect the function of multiple apical
membrane proteins in human tissues in a format suitable for in-depth analysis of ion
channel regulation and interaction. The high-content and high-throughput capacity of this
format will be suitable for the identification of novel modulators of mutant CFTR as well
as other modulators of other channels and transporters implicated in CF pathogenesis.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/cells10123419/s1. Figure S1, Opened organoid density for functional analysis; Figure S2. Gene
expression in opened and 3D organoids; Figure S3. Sodium-dependent ENaC activity validation;
Figure S4. High throughput measurement of ENaC activity.
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